Kah Whye Peng

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. pylori immunostimulatory bacterial transgene”.

Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. pylori immunostimulatory bacterial transgene

Molecular Therapy — Methods & Clinical Development(2022)10.1016/j.omtm.2022.07.014

N/A

0.701DataRank · unranked

22 citations

Michael B. Steele, Ianko Iankov, Susanna C. Concilio, Arun Ammayappan, Brad Bolon +8 more

Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.26.117549

N/A

0DataRank · unranked

19 citations

Timothy S. Carey, Samantha Reiter, Patrycja Lech, Clement W. Gnanadurai, Mulu Z. Tesfay +22 more

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3172

N/A

0DataRank · unranked

1 citations

Tanner Miest, Paul R. Young, Mark L. Gonzalgo, Stephen A. Boorjian, Matthew K. Tollefson +15 more

IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

mSphere(2021)10.1128/msphere.00170-21

N/A

0DataRank · unranked

32 citations

Timothy S. Carey, Samantha Reiter, Chase Lathrum, Patrycja Lech, Clement W. Gnanadurai +18 more

IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

medRxiv(2021)10.1101/2021.02.16.21251653

N/A

0DataRank · unranked

1 citations

Timothy S. Carey, Samantha Reiter, Chase Lathrum, Patrycja Lech, Clement W. Gnanadurai +18 more

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.509

N/A

0DataRank · unranked

8 citations

Bradley C. Leibovich, Tanner Miest, Stephen Bardot, Paul R. Young, Stephen A. Boorjian +14 more

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps657

N/A

0DataRank · unranked

6 citations

Shruthi Naik, Þorvarður R. Hálfdánarson, Konstantinos Leventakos, Kah Whye Peng, Stephen J. Russell +3 more

Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0134

N/A

0DataRank · unranked

25 citations

Rebecca A. Nace, Kah Whye Peng, Miguel Ángel Muñoz-Alía, Stephen J. Russell, Eugene S. Bah

Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14594

N/A

0DataRank · unranked

2 citations

Adam Remick, Nabila Nora Bennani, Joselle Cook, Lianwen Zhang, Thomas E. Witzig +9 more